Renowned cancer research center enters into a Technology Transition agreement with OmniComm to gain more control over the management of their
FT. LAUDERDALE, Fla., Nov. 4 /PRNewswire-FirstCall/ -- OmniComm Systems, Inc. (OTC Bulletin Board: OMCM.OB), a leader in integrated EDC solutions for clinical trials, today announced that after an extensive evaluation of the leading EDC vendors, the Sarah Cannon Research Institute (SCRI), http://www.sarahcannonresearch.com , has chosen to use OmniComm's TrialMaster for their electronic data capture software and services needs. SCRI selected OmniComm for several key reasons, including TrialMaster's functionality. However, the deciding factor was OmniComm's responsiveness and the level of service that the company delivers, something that SCRI requires for their sites.
"Our partnership with OmniComm provides us with site service and support as well as the easy use of their EDC, which allows us to scale our business to meet the demands of our customers," said Phil Cestaro, CFO/CIO of SCRI.
SCRI is one of the largest clinical research programs in the nation, conducting community-based clinical trials in oncology and other therapeutic areas through affiliations with a network of nearly 500 physicians in 24 states. Additionally, SCRI offers management, regulatory and other research support services to drug development sponsors and strategic investigator sites across the country.
"OmniComm's experience in working with world class oncology research centers gives us great satisfaction as a company to know that our cutting edge software is helping to bring novel drugs and therapies to market sooner," said Stephen Johnson, COO of OmniComm. Ken Light, Sr. Vice President of Professional Services for OmniComm added, "Our implementation team stands ready to provide the superior support services needed to effectively transition the use of EDC in-house at the Sarah Cannon Research Center. We are honored to be working with SCRI."
OmniComm Systems, Inc. ( http://www.OmniComm.com ) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc. has corporate headquarters in Ft. Lauderdale, Florida with offices in Bonn, Germany, Tula, Russia, California, Maryland, New York, North Carolina and Texas.
Safe Harbor Disclaimer
Statements about OmniComm's future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm's operations, markets and profitability, actual results could differ materially and adversely from the expected results.
|SOURCE OmniComm Systems, Inc.|
Copyright©2008 PR Newswire.
All rights reserved